MCLEAN, Va. and BUDAPEST, Hungary, May 9 /PRNewswire/ -- Genetic
Immunity, a US/Hungarian clinical-stage Company focused on the development
of its patented nanomedicines for targeted immune amplification, announced
today that the Company will be presenting at the Rodman & Renshaw 5th
Annual Global Healthcare Conference to be held May 19-20, 2008 at the Le
Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The Company's President
and Chief Executive Officer, Dr. Julianna Lisziewicz, is scheduled to
present an overview of the Company's clinical programs on Monday, May 19 at
9:20 a.m. CEST in the Atlantique Salon, Eastern (2nd floor).
For more information on this event please visit:
About Genetic Immunity(R)
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy approved for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform
technology is comprised of two principal components: NanoComp and
DermaPrep. NanoComp is a patented nanoformulation technology that includes
disease-specific plasmid DNA encoded antigens. DermaPrep is the topical
administration device that delivers NanoComp into a patient's lymph node
dendritic cells to induce T cell mediated immune responses that can treat a
broad spectrum of diseases. These two components together make up the
DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp
nanoparticles is specific to HIV and topically delivered via DermaPrep to
amplify the immune system to kill only HIV-infected cells.
The Ruth Group
Sara Ephraim Janine McCargo
|SOURCE Genetic Immunity|
Copyright©2008 PR Newswire.
All rights reserved